More than 90% of CIA patients treated with PBI-1402 did not require blood
MONTREAL, April 23 /PRNewswire-FirstCall/ - ProMetic Life Sciences Inc. (TSX: PLI) ("ProMetic") announces that oral PBI-1402 demonstrates significant activity in patients with chemotherapy-induced anemia ("CIA"), and reduces the need for red blood cell ("RBC") transfusion.
Only 2 patients out of 28 (7%) treated with PBI-1402 required a RBC transfusion, a response rate greater than 90% with regards to this clinical objective. In the March 13, 2008 FDA briefing document, the Oncologic Drugs Advisory Committee emphasizes that the primary objective of treating CIA patients with erythropoiesis-stimulating agents ("ESAs") as being the ability to reduce the need for RBC transfusion. The Advisory Committee cites that approximately 50% of anemic patients receiving chemotherapy required RBC transfusion, and 20%-25% of patients treated with ESAs still required RBC transfusions.
"These results are very exciting and meet the primary objective that formed the basis for FDA approval of other ESAs in CIA patients," states Mr. Pierre Laurin, President and Chief Executive Officer of ProMetic Life Sciences Inc. "This new encouraging data further supports the potential role PBI-1402 could play in the management of anemia in patients with cancer," added Mr. Laurin.
CIA patients enrolled in the study received a once daily oral dose of PBI-1402 during a period of eight weeks while undergoing their normal course of chemotherapy. All patients enrolled have completed the PBI-1402 treatment period.
PBI-1402 is an orally active compound being developed to treat
different types of anemia, such as CIA. PBI-1402 has a distinct mechanism
of action and does not act through EPO receptor. ProMetic has recently
expanded its clinical program for PBI-1402 into the treatment of anemia in
patients with myelodysplastic syndrome
|SOURCE PROMETIC LIFE SCIENCES INC.|
Copyright©2008 PR Newswire.
All rights reserved